Cidara Therapeutics Inc

Cidara Therapeutics — Leerink Partners Rare Disease & Immuno-Oncology Conference 2016

27 slides from Cidara Therapeutics's conference presentation, Sep 28, 2016

  1. Slide 1: New Hope For Serious Infections

    Slide 1: New Hope For Serious Infections

    New Hope For Serious Infections Leerink Partners Rare Disease & Immuno-Oncology Conference Lotte New York Palace New York, NY September 28, 2016 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements These slides and the accompanying oral presentation (the “Presentation”) contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ

  3. Slide 3: Two platforms, multiple programs

    Slide 3: Two platforms, multiple programs

    Two platforms, multiple programs 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 CD101 prophylaxis & other CD101 topical for VVC, Phase 2 CD101 IV for candidemia, Phase 2 CD101 IV for candidemia, Phase 2 CD101 topical for VVC, Phase 2 CD101 prophylaxis & other CD101 Echinocandin Ant

  4. Slide 4: Fungal infections: high mortality

    Slide 4: Fungal infections: high mortality

    U.S. 12-Week Mortality per Annum by Species Fungal infections: high mortality 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Rare Fungi Cryptococcus Aspergillus Candida 2,500 4,500 22,500 67,500 97,000 deaths per year

  5. Slide 5: Echinocandins: first line therapy for candidemia

    Slide 5: Echinocandins: first line therapy for candidemia

    Echinocandins: first line therapy for candidemia DRUG PROFILE First line treatment for Candida Safe and well tolerated Superior to azoles BUT CONSTRAINED Once daily IV Low exposure – suboptimal dosing Growing resistance USD Billions 4.2 0.5 1.1 2.6 Polyenes Echinocandins Azoles

  6. Slide 6: CD101 opportunity: expand echinocandin market

    Slide 6: CD101 opportunity: expand echinocandin market

    CD101 opportunity: expand echinocandin market ACCESS ENTIRE >$4 BILLION MARKET Inpatient & outpatient Treatment & prophylaxis Penetrate azole class Expand indications 4.2 0.5 1.1 2.6 Polyenes Echinocandins Azoles ~2x USD Billions

  7. Slide 7: CD101 – a differentiated echinocandin

    Slide 7: CD101 – a differentiated echinocandin

    CD101 – a differentiated echinocandin 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 ICAAC 2015 Prolongs PK Allows high exposures Eliminates toxic degradation products Enables multiple formulations once weekly dosing treats less susceptible pathogens improved safety & dose range sy

  8. Slide 8: CD101 IV: streamlined development plan

    Slide 8: CD101 IV: streamlined development plan

    CD101 IV: streamlined development plan 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 PK and safety in healthy volunteers Double-blind vs. echinocandin in candidemia Phase I Phase 2 Non-inferiority vs. echinocandin in candidemia IND I II III Phase 3 + invasive candidiasis

  9. Slide 9: CD101 IV Phase I PK

    Slide 9: CD101 IV Phase I PK

    AUC ~2.5x greater AUC ~1.6x higher Once weekly high exposure dosing CD101 IV Phase I PK Cmax 3x higher Anidulafungin 100mg x 7 400mg x 1 200mg x 1

  10. Slide 10: Summary - CD101 IV Phase 1

    Slide 10: Summary - CD101 IV Phase 1

    No serious AEs No withdrawals due to AEs Summary - CD101 IV Phase 1 SAD/MAD Studies PK was dose-proportional and supports once weekly dosing No clinically significant laboratory abnormalities in any CD101 subject Adverse Events (AEs) similar between CD101 and placebo CD101 IV is safe and well-tolera

  11. Slide 11: Phase 2: first of two studies for approval

    Slide 11: Phase 2: first of two studies for approval

    Phase 2: first of two studies for approval CD101 IV 400/400/(400)mg 1 8 Dosing day 15 (optional) 5 Mycological response 14 Mycological & Clinical response 1o END POINT 28 Mycological & Clinical response 35 n=30 CD101 IV 400/200/(200)mg 1 8 Dosing day 15 (optional) 5 14 28 35 n=30 1 7 14 21 28 1 7 14

  12. Slide 12: VVC/RVVC has widespread impact

    Slide 12: VVC/RVVC has widespread impact

    VVC/RVVC has widespread impact 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 OTC Topical 75% have VVC in their lifetime US: 4-5M suffer RVVC Rx Topical or Oral US: 4.4M visits per year

  13. Slide 13: Existing therapies have significant limitations

    Slide 13: Existing therapies have significant limitations

    Existing therapies have significant limitations 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 30-40% women fail acute treatment 50% relapse in RVVC No coverage of non-albicans Candida Increased risk of miscarriage (flucon) CONFIDENTIAL CDC guidelines recommend only using topical a

  14. Slide 14: Phase 2 VVC Study Design

    Slide 14: Phase 2 VVC Study Design

    Phase 2 VVC Study Design DAYS CD101 3% Gel CD101 6% Ointment Fluconazole 150mg 1 2 Dosing day 1 1 1 7 14 21 28 1 7 14 21 28 1 7 14 21 28 Efficacy 7 14 28 n=50 n=50 n=25 Objectives Safety/tolerability of CD101 Gel/Ointment Efficacy of CD101 Gel vs. CD101 Ointment vs. Fluconazole on Days 7, 14, 28 Myc

  15. Slide 15: CD101 Topical development plan

    Slide 15: CD101 Topical development plan

    CD101 Topical development plan Dose-ranging safety & efficacy in VVC patients Phase 2 Phase 3 Superiority in acute VVC 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 IND I II III Phase 3 Superiority in RVVC

  16. Slide 16: Cloudbreak: antimicrobial immunotherapy

    Slide 16: Cloudbreak: antimicrobial immunotherapy

    Cloudbreak: antimicrobial immunotherapy Physically connects the immune system with the pathogen Vaccine Primes the immune system Therapeutic Targets the pathogen The strengths of both systems Cloudbreak™ 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170

  17. Slide 17: Cloudbreak: inspired by cancer immunotherapy

    Slide 17: Cloudbreak: inspired by cancer immunotherapy

    Cloudbreak: inspired by cancer immunotherapy Binds conserved cell surface target EFFECTOR MOIETY Engages innate or adaptive immune system TARGETING MOIETY Small & Large Molecule Microbe Cell 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 TM EM

  18. Slide 18: Return to pre-antibiotic era for Gram negative infections

    Slide 18: Return to pre-antibiotic era for Gram negative infections

    Return to pre-antibiotic era for Gram negative infections Nov Q1 2015 2016 Sources: Liu YY et al. Lancet Infect Dis. 2016 Feb;16(2):161-8. Du H Lancet Infect Dis. 2016 Jan 29. Yao X et al. Lancet Infect Dis. 2016 Jan 29, Bloomberg. AAC 2016 May 26 online; doi:10.1128/AAC.01103-16 Mcr-1 resistance pl

  19. Slide 19: Cloudbreak antibacterial dual mechanism

    Slide 19: Cloudbreak antibacterial dual mechanism

    Cloudbreak™ antibacterial dual mechanism Direct kill: novel TM tightly binds Gram-negative pathogens to kill bacteria 1

  20. Slide 20: Cloudbreak antibacterial dual mechanism

    Slide 20: Cloudbreak antibacterial dual mechanism

    Cloudbreak™ antibacterial dual mechanism Direct kill: novel TM tightly binds Gram-negative pathogens to kill bacteria Immunomodulatory: EM recruits and initiates an immune system response 1 2

  21. Slide 21: CD201 has intrinsic antibacterial activity

    Slide 21: CD201 has intrinsic antibacterial activity

    CD201 has intrinsic antibacterial activity MIC90 against COL-susceptible KAPE pathogens (n=20/species) = 2-4 µg/mL MICs against MDR (aminoglycoside, CRE, COL incl. mcr-1) strains = 2-8 µg/mL CD201 has lower spontaneous mutation freq than COL at 2X MIC (<1.5E-09 vs 2.4E-09) Mutants do not show herita

  22. Slide 22: CD201 efficacy: mouse E. coli septicemia model

    Slide 22: CD201 efficacy: mouse E. coli septicemia model

    CD201 efficacy: mouse E. coli septicemia model 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Mean log10 CFUs/g kidneys P<0.01 LOD 0 1 2 3 4 5 6 7 8 Vehicle + rAb Colistin 1 mpk CD201 3 mpk CD201 3 mpk + rAb

  23. Slide 23: CD201 safety: rat toxicology study

    Slide 23: CD201 safety: rat toxicology study

    CD201 safety: 5 day rat toxicology study 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 CD201 showed no significant histological changes in kidney or liver colistin showed mild to moderate proximal tubule degeneration Unlike colistin, CD201 does not substantially raise urinary albu

  24. Slide 24: Cidara's development pipeline

    Slide 24: Cidara's development pipeline

    Cidara’s development pipeline CD101 Cloudbreak™ IV Topical Antibacterial Antifungal Antiviral Discovery in vitro in vivo IND Enabling Phase 1 Phase 2

  25. Slide 25: Financial Information

    Slide 25: Financial Information

    Financial Information 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Summary Information At 6/30/2016 Cash, cash equivalents and marketable securities $87.1 million Shares issued 14.0 million Fully-diluted shares1 16.1 million 1 Includes 2.1 million outstanding stock options; exclu

  26. Slide 26: 2016 Milestones

    Slide 26: 2016 Milestones

    2016 Milestones 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Program Next Milestone Expected Timing CD101 Topical Phase 2 start Mid 2016 ✓ CD101 IV Phase 2 Start Mid 2016 ✓ Cloudbreak Platform Development candidate Q4 2016 ✓

  27. Slide 27: New Hope For Serious Infections

    Slide 27: New Hope For Serious Infections

    New Hope For Serious Infections Leerink Partners Rare Disease & Immuno-Oncology Conference Lotte New York Palace New York, NY September 28, 2016 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170

Source: SEC EDGAR · 8-K filed Sep 28, 2016

More decks from Cidara Therapeutics Inc